Skip to headerSkip to main contentSkip to footer
Get our Free E-newslettersGet our Free E-newsletters
Kiplinger logoLink to homepage
Get our Free E-newslettersGet our Free E-newsletters
Subscribe to Kiplinger
Subscribe to Kiplinger
Save up to 76%
Subscribe
Subscribe to Kiplinger
  • Store
  • Home
  • Investing
  • Retirement
  • Taxes
  • Personal Finance
  • Your Business
  • Wealth Creation
  • More
    • Podcasts
    • Economic Outlooks
    • Tools
  • My Kiplinger
    • Kiplinger's Personal Finance Magazine
    • The Kiplinger Letter
    • The Kiplinger Tax Letter
    • Kiplinger's Investing for Income
    • Kiplinger's Retirement Report
    • Store
    • Manage My E-Newsletters
    • My Subscriptions
  • Home
  • investing
  • stocks
  • small cap stocks
small cap stocks

5 Cheap Stocks to Buy for $10 or Less

Cheap stocks are flush with risk and aren't for the faint of heart. But these five names offer compelling bull cases for those willing to stomach uncertainty and volatility.

by: Patrick Sanders
June 30, 2020

Getty Images

Cheap stocks are effectively Wall Street's casino. It's OK to play them for fun once in a while – just don't make a habit of it.

Stocks come in all shapes, sizes and prices. Right now, some of the largest companies on earth include Amazon.com (AMZN) and Google parent Alphabet (GOOGL), both of which trade at four-figure prices. While nominal prices broadly don't mean much – a company with a $50 stock might be every bit as solid as a company with a $250 stock – these firms' outsize stock prices (and more importantly, their roughly trillion-dollar market values) reflect a long track record of success, not to mention extremely stable financial positions.

On the other end of the spectrum are small caps and even micro-caps: typically cheap stocks that trade for such low prices for a reason.

Investors often gravitate toward cheap stocks in part because of the psychological appeal of being able to buy many shares for a small dollar cost. Also, these stocks are often subject to bigger price swings, making it seemingly easier to reap big gains in a short time.

But institutional investors often do the opposite. Sometimes they bow out once a stock dips below $10, and more will exit once share prices dive below $5. That's because while nominal prices typically don't matter, when they're low enough, they reflect higher risk. Some stocks trading in single digits are in long-term decline. Very low stock prices often reflect smaller market values, and lower-value companies are more susceptible to "pump and dump" schemes. Also, the major exchanges have a $1-per-share minimum trading threshold – stocks that trade under this for long enough risk being delisted.

Even good cheap stocks to buy carry significant risks, such as high debt loads or narrow revenue streams.

Here, we've identified five cheap stocks to buy for their promising potential. In each case, they've caught the eye of at least one or two analysts; like institutional investors, Wall Street's analyst community often turns away from sub-$10 stocks. Just remember: These are extremely risky positions that can move in a hurry. If you invest in these at all, do so in small amounts that you can afford to lose. Also, use limit orders and stop-losses when speculating in cheap stocks, and monitor their prices carefully.

Data is as of June 29.
  • 19 of the Best Stocks You've Never Heard Of

1 of 5

LiveXLive Media

Getty Images

  • Market value: $195.6 million

Since the start of the pandemic, one thing many people have grown to miss is live music – everything from concerts to club performances to dance-hall shows.

Fortunately, LiveXLive Media (LIVX, $3.28) doesn't rely exclusively on in-person events – and it shows given a more-than-doubling of shares despite most such performances being shut down. The digital media company, which acquires, distributes and monetizes live music, can do the same thing with internet radio, streaming music and video content.

That market has been a promising one as people head online to entertain themselves. LiveXLive says it has sold more than 17,000 pay-per-view tickets in 96 countries since announcing PPV and digital touring in May, averaging $27 a pop. And this week, LIVX said its international pay-per-view event with K-pop (Korean pop) artist Monsta X sold out of all $150 VIP packages in two minutes as part of an event to be streamed on July 25.

Its most recent event – a livestream involving retired NBA superstar Shaquille O'Neal and Tampa Bay Buccaneers tight end Rob Gronkowski – received more than 9 million views. That has driven LiveXLive's total livestream views to more than 78 million this year. The company also announced on June 29 that paid subscribers had reached a record 873,000.

Earlier in June, the company announced record full-year fiscal 2020 revenues of $38.7 million, up from $33.7 million a year ago.

The thing to watch for here, however, is that while the company's revenues are growing rapidly, its losses are piling up quickly, too. LiveXLive hasn't turned an annual profit since coming public in late 2017, and they've grown each year since then.

Nonetheless, Alliance Global Partners' Brian Kinstlinger has LIVX among his cheap stocks to buy. The analyst raised his price target in June from $5.50 per share to $6, citing a "rich portfolio" of live events, stream-from-home, podcasts and PPV events. He also sees the company's new direct sales force driving better monetization. Ladenberg analyst Jon Hickman also raised his price target, from $4.50 to $5.75, citing the company's increasing subscriber growth. In fact, over the past three months, LIVX has received nothing but Buy calls from the six analysts who have sounded off on the stock.

  • 11 Small-Cap Stocks Analysts Love the Most

2 of 5

Evoke Pharma

Getty Images

  • Market value: $86.0 million

No list of cheap stocks to buy would be complete without a pharmaceutical/biotech name or two, which typically have enormous quick-movement potential on the strength (or weakness) of trial data.

Evoke Pharma (EVOK, $3.48) is one such name. The stock has more than doubled in 2020, in large part on excitement for its Gimoti nasal spray, which recently received approval from the U.S. Food and Drug Administration.

Gimoti, which goes under the generic name metoclopramide, is unique because it's the only nasally administrated product that has approval to treat gastroparesis, a condition that prevents the stomach from contracting and interferes with digestion. Other such drugs are administered orally. However, Evoke believes its treatment will be more effective because it bypasses the GI system and directly enters the bloodstream.

"Many times, patients do not experience adequate relief of their gastroparesis symptoms from current treatments, representing a significant need for a new approach to therapy," Evoke CEO Dave Gonyer said in a release.

The approval allows Evoke to access a $5 million credit line to help fund manufacturing and commercialization. The good news is that unlike many smaller biotechs that are saddled with high debt, EVOK is sitting on $4.1 million in cash against virtually no debt.

Like many cheap stocks, EVOK is thinly followed by the Wall Street crowd. However, H.C. Wainwright analyst Raghuram Selvaraju upgraded Evoke Pharma's shares from Neutral to Buy following the FDA approval and set a 12-month price target of $10 – almost triple current prices. Assuming a "modestly-paced trajectory" of $14 million in Gimoti sales in 2021, Evoke could be cash-flow breakeven by the first half of 2020, Selvaraju writes.

  • 7 Biotech Stocks Wall Street Says Will Double or More

3 of 5

AIM ImmunoTech

Getty Images

  • Market value: $83.5 million

As important as GI issues are, the medical community – and the stock market – is heavily focused on research related to treating, curing and preventing COVID-19.

AIM ImmunoTech (AIM, $2.56) is a Florida-based biotech company with an entry in the COVID-19 product pool: Ampligen (rintatolimod), which treats severely debilitated patients with chronic fatigue syndrome. The FDA in May authorized human trials to assess Ampligen's effectiveness, along with an interferon known as alfa-2b, in clearing the upper airway of cancer patients who have COVID-19.

AIM also has filed an application in the U.S. for Ampligen to treat chronic fatigue induced by COVID-19. Ampligen already has been approved in Argentina to treat myalgic encephalomyelitis/chronic fatigue syndrome; COVID-induced chronic fatigue shows similarities to ME/CFS.

"Worldwide, we may still be in early stages of the pandemic," AIM ImmunoTech CEO Thomas Equels said in a release. "As a result, we believe there exists a significant risk of SARS-CoV-2 induced chronic fatigue among the millions of survivors of COVID-19, as we have witnessed in the prior SARS-CoV-1 epidemic."

Like many health and pharmaceuticals fighting COVID-19, AIM ImmunoTech's shares have soared in 2020, from below 60 cents at the start of the year to well above $2 now.

AIM, which also is thinly covered, has received three Buy ratings from the three analysts who have sounded off about it in 2020. Most recently, Maxim analyst Jason McCarthy maintained a Buy target on shares in April and raised the price target from $2 per share to $5, saying the market capitalization of $75 million didn't yet capture the value of Ampligen's potential. While AIM has improved since then, shares are still well below his PT.

  • 7 Growth Stocks to Buy for Oodles of Upside

4 of 5

iBio

Getty Images

  • Market value: $294.7 million

Next on our list of cheap stocks to buy is iBio (IBIO, $2.46) – another coronavirus play.

Shares spiked from a quarter per share to start the year to nearly $2.46 in late February. While prices receded during the broader market downturn, they recently shot back up again near their 2020 highs. All told, the stock has nearly tripled over the past 52 weeks, albeit in an extremely rocky fashion.

So why this on-again, off-again enthusiasm for IBIO stock?

It comes down to iBio's "FastPharming" technology. The company believes its unique plant-based protein production system will allow whoever has a vaccine to scale production quickly – and that's essential for combating a global pandemic. The firm says it can create 500 million doses of a COVID-19 vaccine annually from its Texas facility; iBio currently has two vaccine programs in preclinical studies now.

Last week, Alliance Global Partners initiated covered of IBIO stock with a Buy rating and a price target of $2.75. Analyst Ben Haynor said the company's transition to becoming a specialized contract development and manufacturing organization (CDMO) makes it "well-positioned to be part of the coronavirus solution."

Note, however, that iBio does have an unenviable net debt position (debt minus cash) of $23.5 million, according to S&P Capital IQ data. Moreover, the company has been generating steeper net losses for years, including $17.6 million of red ink for its fiscal year ended June 2019.

  • 14 Best Tech Stocks That Aren't on Your Radar

5 of 5

Envela

Getty Images

  • Market Value: $158.9 million

Many cheap stocks belong to companies that are on the younger side, but Envela (ELA, $5.90) – which buys and sells luxury goods such as diamonds, watches and even bullion – has been around since 1965. The company's customers include everyone from individual consumers and retailers to recycling and IT asset disposition firms.

Envela isn't exactly a "feel-good" organization in that it's best-positioned for success if the U.S. is headed down the path of an extended recession. That's not necessarily a bad bet to make right now, either.

Unemployment remains in double digits, and federal stimulus payments and mortgage and rent forgiveness programs are set to expire soon. The Federal Reserve has indicated that it's prepared to keep interest rates near zero through at least 2022 – a signal that the nation's leading economists are digging in for a long downturn, too. Gold prices have jumped by about 18% to nearly $1,800 per ounce, too, which benefits Envela's operations.

Indeed, for the March quarter, Envela reported a 61.2% year-over-year jump in revenues, and profits shot to 4 cents per share from a penny per share in the year-ago quarter. "Our business got off to a strong start in 2020, resulting in one of the biggest quarters in Envela's history: CEO John Loftus said in the quarterly earnings release.

Just be careful, and perhaps wait for a volatility-induced pullback before trying to ride ELA higher. The stock has already surpassed its most recent analyst price target. In May, Argus Research's Steve Silver said the stock was a compelling value despite more than doubling its share price. But his new PT was $5, which the company eclipsed this week.

Nonetheless, Envela could continue to reap profits if the economic recovery stalls and gold prices continue to climb.

  • 50 Top Stocks That Billionaires Love
  • small cap stocks
  • stocks
  • investing
Share via EmailShare on FacebookShare on TwitterShare on LinkedIn

Recommended

Stock Market Today 1/22/21: Nasdaq Scratches Out Another Record Finish
Stock Market Today

Stock Market Today 1/22/21: Nasdaq Scratches Out Another Record Finish

The Nasdaq came out of a mixed day with yet another fresh high. More interesting were Friday's moves by IBM, Intel and GameStop.
January 22, 2021
Why GameStop (GME) Stock Has Gone on an Epic Tear
stocks

Why GameStop (GME) Stock Has Gone on an Epic Tear

GameStop has rocketed 2,419% since April. However, recent heat under GME shares has been fueled not just by good news, but also doubters calling it qu…
January 22, 2021
SEC Dings Robinhood for Trading Charges
Business Costs & Regulation

SEC Dings Robinhood for Trading Charges

The complaints are a reminder to investors who pay low or no commissions to investigate more-opaque costs.
January 21, 2021
Stock Market Today 1/21/21: Big Tech Keeps the Rally Moving
Stock Market Today

Stock Market Today 1/21/21: Big Tech Keeps the Rally Moving

While Biden got to work on a number of new COVID-fighting measures Thursday, Wall Street kept its eye on mega-cap technology firms.
January 21, 2021

Most Popular

When Could We Get a Third Stimulus Check?
Coronavirus and Your Money

When Could We Get a Third Stimulus Check?

President Biden and others in Congress are pushing for a third-round of stimulus checks, but it might be a while before we get them.
January 20, 2021
Where's My Stimulus Check? Use the IRS's "Get My Payment" Portal to Get an Answer
Coronavirus and Your Money

Where's My Stimulus Check? Use the IRS's "Get My Payment" Portal to Get an Answer

The IRS has an online tool that lets you track the status of your second stimulus check.
January 18, 2021
20 Best Stocks to Buy for the Joe Biden Presidency
stocks to buy

20 Best Stocks to Buy for the Joe Biden Presidency

Joe Biden has been sworn in as America's 46th president. These are 20 of the best stocks to own under the new administration.
January 20, 2021
  • Customer Service
  • About Us
  • Advertise With Us (PDF)
  • Privacy Policy
  • Cookie Policy
  • Kiplinger Careers
  • Accessibility
  • Privacy Preferences

Subscribe to Kiplinger's Personal Finance

Be a smarter, better informed investor.
Save up to 76%Subscribe to Kiplinger's Personal Finance
Dennis Publishing Ltd logoLink to Dennis Publishing Ltd website
Do Not Sell My Information

The Kiplinger Washington Editors, Inc., is part of the Dennis Publishing Ltd. Group.
All Contents © 2021, The Kiplinger Washington Editors

Follow us on InstagramFollow us on FacebookFollow us on TwitterConnect on LinkedInConnect on YouTube